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404Non-motor Parkinson disease: new concepts
and personalised management
Nataliya Titova1, K Ray Chaudhuri2Summaryon-motor symptoms (NMS) of Parkinson disease (PD)
were recognised by James Parkinson, a London-based  Most patients with Parkinson disease (PD) have non-motor
symptoms (NMS), and on average these can range from four
to 19 different symptoms.
 NMS dominate the prodromal phase of PD and some may
serve as clinical biomarkers of PD.
 NMS can be dopaminergic, non-dopaminergic, of genetic
origin or drug induced.
 Clinical assessment of NMS should include the NMS
Questionnaire (completed by patients) for screening, as
recommended by the International Parkinson and Movement
Disorders Society and other international societies.
 The total number of NMS in a patient with PD constitutes the
NMS burden, which can be graded using validated cut-off
scores on the NMS Questionnaire and Scale and can be
used as an outcome measure in clinical trials.
 Despite NMS burden having a major effect on the quality of life
of patients and carers, a large European study showed that
NMS are often ignored in the clinic.
 The syndromic nature of PD is underpinned by non-motor
subtypes which are likely to be related to speciﬁc dysfunc-
tion of cholinergic, noradrenergic, serotonergic pathways in the
brain, not just the dopaminergic pathways.
 NMS can be treated by dopaminergic and non-dopaminergic
strategies, but further robust studies supported by evidence
from animal models are required.
 The future of modern treatment of PD needs to be supported
by the delivery of personalised medicine.Nphysician in his 1817 essay on the condition he called
“the shaking palsy” or “paralysis agitans”.1 He described a com-
plex conditionwith tremor, gait abnormalities and stoopedposture
intermixed with NMS such as sleep dysfunction, delirium, de-
mentia and dysautonomia. However, NMS remained under-
recognised and poorly researched until the introduction of
comprehensive tools such as the NMS Questionnaire (https://
www.pdnmg.com/imagelib/pdf/nms-quest.pdf) and NMS
Scale (https://www.pdnmg.com/imagelib/pdf/nms-scale08.
pdf) in the early 2000s, and the recognition of PD as a condition
of many origins, termed the Parkinson complex in 2006 and sub-
sequently classiﬁed as a syndrome in 2017.2-4 The assessment tools
have helped to assess NMS holistically and to outline the effect of
their burden on quality of life in PD.5,6 NMS assessment in the
outpatient clinic is now considered to be good clinical practice in
many countries. Recent attempts to redeﬁne PDhave viewed it as a
complex combination of motor and non-motor disorders, with a
natural history that includes a prodromal phase dominated by a
range of NMS. NMS-driven biomarkers may deﬁne prodromal PD
and enable the identiﬁcation of patients at risk of developingmotor
PD and the development of new neuroprotective therapies. Vali-
dated burden grading of NMS is also being increasingly used as an
outcome measure in clinical trials.7,8 Finally, the complex multi-
neurotransmitter dysfunction of PD may underpin recently
described non-motor subtypes.4 Recognition of such subtypesmay
to lead to the emergence of personalised and precision medicine in
the management of PD.9
This narrative review is based on a PubMed review of original and
review articles from 1999 to 2017 as well as specialist society
publications and relevant guidelines to formulate an evidence-
based overview of the topics, as applied to clinical practice.
Non-motor symptoms in Parkinson disease
PD is the second most common neurodegenerative disorder in
the world, with a global prevalence of about 200 per 100 000
individuals.10 About one person is diagnosed every hour, one
in 50 people over 80 years of age are likely to be diagnosed
with PD, and about 10% of those diagnosed are below 40 years
of age.10 The number of people with PD is rising worldwide
because of increasing life expectancy, and the number of di-
agnoses is expected to double by 2040. PD is now recognised
to be as much a non-motor disorder as a motor disorder, with
a complex range of NMS present in the prodromal stage as
well as in the various motor disorder stages until the ﬁnal
palliative stage11,12 (Box 1).
Prodromal non-motor Parkinson disease
The prodromal period of PD is now well established (Box 1). This
phase is recognised by a range of NMS which include hyposmia,1 Pirogov Russian National Research Medical University, Moscow, Russia. 2Maurice Wohl C
nattitova@yandex.ru j doi: 10.5694/mja17.00993rapid eye movement sleep behaviour disorder (RBD) and other
NMS shown in Box 2. Several cohort studies are in progress to
establish how best to determine this prodromal period, whichmay
last up to 10 years. The International Parkinson and Movement
Disorder Society (MDS)has also attempted todeﬁne theprodromal
period based on several NMS (eg, RBD, hyposmia, constipation,
excessive daytime constipation), as well as some motor features
(eg, abnormal quantitative motor testing) and other factors (eg,
age, occupational exposure to solvents or pesticides, smoking,
family history), and then calculate a likelihood ratio for later
development of manifest PD.13 Identiﬁcation of the prodromal
period is of crucial importance to enable early initiation of neuro-
protective therapies at a stagewhenmolecular degenerationbegins
rather than waiting until motor symptoms commence. Mutations
in glucocerebrocidase or leucine-rich protein kinase genes have
been implicated to mark an even earlier (pre-prodromal) stage of
PD when there are no symptoms but susceptibility to PD exists
(Box 1). Imagingusingpositron emission tomography, transcranial
ultrasound and cardiac meta-iodobenzylguanidine (MIBG) scans
have all been suggested as possible biomarkers in the prodromal
period of PD. More recently, the role of skin biopsy as an
RBD biomarker has been proposed, and cardiac MIBG scanning is
now included as a supportive criterion for the clinical diagnosis
of PD.11,13,14linical Neuroscience Institute, King’s College London, London, UK.
1 Natural history pattern of Parkinson disease (PD)
MIBG ¼meta-iodobenzylguanidine. NMS ¼ non-motor symptoms. PET ¼ positron emission tomography. REM ¼ rapid eye movement. Note that the neuronal loss in PD is unlikely
to follow a linear pattern (as suggested in the ﬁgure) and the relevant dotted line is a schematic representation. Imaging using transcranial ultrasound, PET and MIBG scans may
be useful as markers in the prodromal period and possibly the pre-prodromal period. Skin biopsy may also be useful in patients with REM sleep behaviour disorder. Reproduced
with permission from Titova et al.11u
3 Frequency of occurrence of a range of non-motor
symptoms (NMS)*,15
Non-motor symptoms Mean Range
Cognitive
Memory 46% 38e63%
Concentration 39% 30e50%
Narrative reviewThe burden of non-motor symptoms
NMShas been studied using validated tools and cluster analysis in
untreated de novo PD, early and advanced treated PD and multi-
racial cohorts.15 The range of different NMS ascertained from these
studies using the NMS Questionnaire is shown in Box 3. From a
global perspective, the average number of NMS per patient varies
from 4 to 19 comparedwith controls where the scores range from 2
to 12.15 Urinary dysfunction appears to be one of the most
commonly reported NMS across several studies, followed by
constipation, memory problems, anxiety and depression, fatigue
and insomnia. Urinary dysfunction appears to be present
throughout the spectrum of PD, being a particular challenge in the
advanced palliative stage.2 Prodromal non-motor symptoms and potential risk of
development of motor Parkinson disease (PD)
Non-motor symptom PD risk
REM sleep behaviour
disorder
80% progression to a-synucleinopathy
in approximately 10e12 years
REM sleep behaviour
events
Polysomnography evidence of developing
REM sleep behaviour disorder
Late-onset hyposmia/
anosmia
Progression to motor PD
Episodic major depression Prodromal PD feature
Constipation Higher risk of developing PD
Excessive daytime
somnolence
Higher risk of developing PD
Fatigue Higher risk of developing PD
Abnormal colour vision/
visual perception
Higher risk of developing PD
Erectile dysfunction Higher risk of developing PD
Pain (often unilateral) Pain often evident on side ﬁrst
affected at motor PD diagnosis
Cognitive impairment Recent evidence of prodromal
feature from PPMI cohort studies
PPMI ¼ Parkinson Progression Marker Initiative. REM ¼ rapid eye movement.uIt is now recognised that rather than considering the effect of a
singleNMS, it is the total number ofNMSpresent in apatient— the
NMS burden — that determines quality of life.16,17 Globally, the
rising number of people diagnosed with PD has a directDepression
Sadness 43% 23e56%
Anxiety 43% 31e56%
Sleep
Excessive daytime sleepiness 31% 21e37%
Insomnia 41% 18e53%
REM sleep behaviour disorder 34% 30e39%
Restless legs syndrome 36% 28e41%
Fatigue 42% 31e58%
Pain 31% 18e46%
Gastrointestinal
Swallowing 25% 16e30%
Constipation 47% 28e72%
Urinary
Urgency 53% 35e61%
Nocturia 54% 26e67%
NMS Questionnaire (global comparison)
Parkinson disease patients 8 4e19
Healthy controls 4 2e12
REM ¼ rapid eye movement. * Based on international cohort studies using the Non-
motor Symptoms Questionnaire. Data for NMS Questionnaire (global comparison)
are number of symptoms.u
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406consequential effect on theNMS burden, asNMS occur in virtually
every patient with PD.5,8,18 The NMS burden has a direct inverse
relationship with quality of life, and the frequent occurrence of
NMShas led to attempts to revise our current understanding of PD
(Appendix 1). Using multiple linear regression analysis, Martinez-
Martin and colleagues showed that the correlation of quality-of-life
measures in PDwas stronger with NMS total score determined by
the NMS Scale compared with motor symptoms and complica-
tions.6 International validation studies of the NMS Scale showed a
highly signiﬁcant inverse associationwithworsening quality of life
and increasing NMS burden.7,19 Similar data have also been found
with theNMSQuestionnaire.8 In the late andpalliative stage of PD,
the impact of NMS is of great importance and contributes to hos-
pitalisation and institutionalisationwith high cost to society.20,21 A
large scale naturalistic Italian study of over 1000 patients also
conﬁrmed that quality of life was signiﬁcantly worse in those with
NMS compared with those without NMS.17Classiﬁcation of non-motor symptoms
NMS have non-dopaminergic and dopaminergic origins and vary
widely in their nature, range and presentation.5 It is important not
to regard all NMS together as a single entity, and sub-classiﬁcation
of NMS helps develop and deliver true personalised medicine
strategies for PD. Classiﬁcation of NMS based on source of origin
has been attempted and is shown in Box 4.16,174 A modern classiﬁcation of non-motor symptoms (NMS) in
Parkinson disease15,16
Dopaminergic or partial dopaminergic origin
 depression
 apathy
 early cognitive dysfunction
 wearing-off related, and aspects of central pain
 impaired colour vision
 hallucinations
 sensory, cognitive and autonomic symptoms of non-motor function
 restless legs syndrome
Non-dopaminergic origin (some dopaminergic inﬂuence is possible)
 anxiety
 dysautonomia
 hyposmia
 dementia
 fatigue
 sleep dysfunction (rapid eye movement sleep behaviour disorder,
excessive daytime somnolence, insomnia)
Drug or concurrent illness (comorbidity)-induced (addition or
withdrawal)
 hallucinations, other psychosis, delirium, delusion
 impulse control disorders
 dopamine agonist withdrawal syndrome
 non-motor ﬂuctuations
 Parkinson hyperpyrexia syndrome
Genetically determined
 Mild cognitive impairment or dementia in glucocerebocidase
mutation cases
 Sleep dysfunction in LRRK2 mutation casesuNeuropathology and animal models
A range of pathophysiological mechanisms operates to start and
continue the neurodegenerative process of PD (Box 5).4 Dysfunc-
tions in the dopamine pathways in the brain and periphery are a
major problem, but other major neurotransmitters such as acetyl-
choline, noradrenaline and serotonin are also involved.4 Some-
times, the involvement of the non-dopaminergic pathwaysmay be
greater than dopaminergic involvement, supporting the concept of
cholinergic, serotonergic and noradrenergic subtypes of PD.2-4,16
Braak and colleagues22,23 proposed six pathways of propagation
of the pathological process in PD, commencing in the medulla and
moving upwards. The proposal is based on Lewy body deposition
in the brain. Stage one is associated with involvement of the ol-
factory bulb, anterior olfactory nucleus and the lower medulla.
Stage 2 involves the lower brainstem containing non-
dopaminergic nuclei such as the median raphe (serotonin) and
locus coeruleus (noradrenaline) among many others. Neuro-
degeneration in these areas correlates clinically with late-onset
hyposmia as well as RBD, which is now recognised as one of the
key prodromal clinical biomarkers for the development of de-
mentia as well as synucleinopathy, with over 80% risk of pheno-
converting at 10 years.24 Hyposmia is included as a supportive
criterion for diagnosis of PD.13 Stages 3 to 6 chart the progression of
the pathological process of PD from the substantia nigra to the
subcortical regions such as the basal ganglia and then the cortical
area of the brain, the latter underpinning cognitive decline in
advanced stages of PD.
The proportion of patients who go through all the pathological
stages, and the rate of progress through these stages, is unclear. The
progression pattern of PD varies and some patients may be
reasonably active and independent even 20 years after the motor
diagnosis of PD.25 Controversies surrounding the concept of
advanced PD have recently been reviewed by Titova and col-
leagues.26 Broadly, however, most patients progress to advanced
palliative stage by about 15 years after the onset of motor PD (with
a variable length of prodromal period). Some initial clinical5 Pathophysiological processes likely to be involved in the
pathogenesis of Parkinson disease (PD)4
 Genetic and epigenetic mechanisms
< LRRK2, GBA mutations
< Ethnic susceptibility to PD
< Ashkenazi Jewish population
< Inuit populations
< Susceptibility to organic toxins (insecticides)
< Environmentegene interaction (higher risk in agricultural
communities, lower in smokers)
 Abnormalities in a-synuclein
< Misfolding, oligomers, altered proteostasis, neurotoxicity
< Synaptic dysfunction
< Ageing brain susceptibility
< Gutebrain axis-driven prion-like intra-axonal transport
< Altered intestinal microbiota
 Central and extra-cerebral neuroinﬂammation (trigger misfolding
of a-synuclein)
 Amyloid and Tau deposition (older PD and PD dementia)
 Mitochondrial dysfunction/reduced complex 1 activity (cell damage
and death)
 Altered gut microbiota (reduced mucin and inﬂammatory spread
to brain [gutebrain axis])
 Neurotransmitter dysfunction (altered signalling in brain)u
6 A proposed algorithm for a combined motor and non-motor
assessment of non-motor symptoms (NMS) in the clinic to
determine a patient’s non-motor status*
CISI-PD ¼ Clinical Impression of Severity Index for Parkinson Disease. MDS ¼Movement Disorders
Society. UPDRS ¼ Uniﬁed Parkinson Disease Rating Scale. *All cut-off values quoted are validated
from clinical studies. Rapid assessment in the clinic could be performed using Hoehn and Yahr
motor staging and the self-completed NMS Questionnaire and subsequent burden grading.
Adapted with permission from Katunina and Titova.15u
Narrative reviewbiomarkers may suggest relatively rapid progression of
PD and include patients with RBD and dysautonomia at
the onset of the illness or those with early gait-related
problems.
The peripheral nervous system, spinal cord as well as
multiple viscera and skin are involved in PD and may ex-
press a range of NMS (Appendix 2).27,28 Neuropathology
including a-synuclein deposition is seen in peripheral or-
gans suchas theheart, gut, submandibular glandsandskin,
indicating the widespread involvement of the peripheral
nervous system in PD. The spread of a-synuclein deposi-
tion and consequent clinical non-motor effects have
recently been reviewed by Jellinger.27 Peripheral tissue bi-
opsy may emerge as a feasible biomarker for some speciﬁc
NMS in PD, and skin biopsy has been proposed as a po-
tential biomarker in RBD.14
To properly understand NMS in PD, robust animal
models that express progressive neurodegenerationwith
Lewy body formation are required. Currently, there are
no such models. Experimental animal models can assist
in understanding the pathogenesis of the range of NMS,
which in turn can help with potential approaches to their
treatment. Knowledge of current developments in rela-
tion to attempts at producing animal models is therefore
important to understand the pathophysiology of NMS in
PD as well as to develop new treatments, currently a key
unmet need. A list of potential animal models with a7 Factors that may drive or enable pathways for personalised
and precision medicine in Parkinson disease (PD)
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Non-motor symptom clinical measurement
Holistic and widely validated tools such as the NMS Question-
naire30 and Scale31 are available and are recommended by the
MDS. TheNMSQuestionnaire is a self-reporting tool completed by
patients and is instrumental as a ﬂagging tool in the clinic that is
useful for epidemiological studies.
Holisticmeasurements ofNMSare nowsupported by validation of
the grading of burden using the NMSQuestionnaire8 and Scale7,32
(Appendix 1). To ensure that the NMS status of patients with PD is
assessed in parallel with their motor symptoms, recent reviews
have recommended that the NMS assessment tools be used in
combination with motor assessment (Hoehn and Yahr staging).33
A key recommendation would be to combine Hoehn and Yahr
staging with the NMS Questionnaire grading for patients, per-
formed at least once a year. A suggested paradigm for use in the
clinic is shown in Box 6. Additional tools include the Uniﬁed PD
Rating Scale, the Clinical Impression of Severity Index for PD, as
well as a wearing-off questionnaire to address non-motor ﬂuctu-
ations. TheUniﬁed PDRating Scale is themostwidely used clinical
scale for PD worldwide, and the Clinical Impression of Severity
Index for PD has been speciﬁcally validated. Combined use for
gradation strategies incorporating motor and non-motor mea-
surements have been reviewed recently.34,35Reproduced with permission from Titova and Chaudhuri.9u
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Non-motor ﬂuctuations almost always accompany motor ﬂuctu-
ations and have been classiﬁed into autonomic, sensory and
cognitive subtypes. Storch and colleagues36 have described NMS
that are present exclusively during off periods, while others are
present during on periods and worsen during off periods. Clini-
cally, non-motor ﬂuctuations usually manifest with anxiety, pain,
drenching sweats, clouding of mind, fatigue and depression.However, some NMS such as euphoria may occur exclusively
during on periods.Non-motor subtyping
Non-motor subtypes have been described using multi-
dimensional cluster analysis studies in untreated patients and those
with early PD. These report discrete clusters of patients expressing
speciﬁc NMS.37,38 Clinical characterisation of these clusters
8 A summary of the various components and strategies proposed to
establish a comprehensive and holistic personalised medicine
strategy for Parkinson disease (PD)
DDS ¼ dopamine dysregulation syndrome. DRT ¼ dopamine replacement therapy.
GBA ¼ glucocerebrocidase. HD ¼ histone deacetylase. ICD ¼ impulse control disorder.
LD ¼ levodopa response. LRRK2 ¼ leucine-rich repeat kinase 2. PD ¼ Parkinson disease.
Reproduced with permission from Titova and Chaudhuri.9u
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408identiﬁes speciﬁc NMS dominant phenotypes: Park cognition, Park
apathy, Park depression/anxiety, Park sleep, Park pain, Park
fatigue and Park autonomic.34,39-41 Further cohort studies are
required to deﬁne the speciﬁc clinical characteristics of these sub-
types as well as biomarkers and natural history. A more relevant
neurotransmitter dysfunction-based non-motor classiﬁcation has
been proposed by Titova and colleagues,4 supported by imaging
and other biomarker studies. This classiﬁcation forms the basis of
the concept that PD may well be a syndromic condition associated
with a range of complex disorders underpinned by speciﬁc neuro-
transmitter deﬁcits. The cholinergic syndrome has been well char-
acterised clinically42 and in de novo PD,43 and cholinergic imaging
of thebrainand thegut supports this concept.44-47 Suchpatientsmay
have a higher risk of progression to dementia.46 Noradrenergic
syndrome is also well characterised and patients express domi-
nantly autonomic dysfunction.48 Patients with the serotonergic
subtype, however, suffer from severe fatigue and may develop
levodopa-induced dyskinesias.49 These neurotransmitter-driven
syndromic presentations4 underpin the modern concept of
personalised medicine for PD.9Treatment of non-motor symptoms
Management of NMS in PD presents one of the key challenges in
clinical practice. An evidence-basedmedicine reviewby theMDS50
and a recent review by Schrag and colleagues51 highlight key un-
met needs. The role of non-pharmacological therapies, such as
various forms of exercise (yoga, tai chi), cognitive behaviour
therapy and transcranial magnetic stimulation, is being explored,
particularly for depression, anxiety and cognitive problems.
Increasing attention has focused on probiotic treatment for
abnormal gut ﬂora in PD. However, for many NMS, such asfatigue, sexual dysfunction, apathy, and urinary
dysfunction, there is insufﬁcient evidence of treatment.Personalised medicine
Personalised medicine is the modern way of delivering
an individualised holistic PD treatment strategy.9,52
Personalised medicine thus encompasses several
strands of treatment known as the enablers. From a
pharmacological point of view, it should involve
dopaminergic and non-dopaminergic strategies. In
addition, there are sub-strategies involving precision
and tailored medicine to suit the needs and re-
quirements of individual patients. Precision medicine is
relevant for patients who may be at risk of developing
the clinical syndromeofPDas identiﬁedby speciﬁc gene
mutations. Precisionmedicine in this scenario attempts
to be preventive. Tailored medicine works with the
single multi-factorial complex nature of PD to manage
symptoms and develop subtype-speciﬁc strategies.
Personalised medicine is now being applied to other
conditions such as stroke, mental health, oncology
as well as diabetes. In PD, neurotransmitter subtype-
based individualised treatment can be considered.
Patients with the cholinergic subtype could be
treated by a combination of dopaminergic and
cholinesterase inhibition therapy while also under-
taking active counselling regarding lifestyle, job,
exercise and freezing of gait.46 Patients with the
noradrenergic subtype would require a focus onnoradrenergic treatment for dysautonomia, whereas patients
with serotonergic subtype fatigue could be managed by sero-
tonin active drugs. However, robust clinical trials for such
strategies are not available and trials are in progress.
Several factors inﬂuence the delivery of personalised medicine in
PD (Box 7). A summary of pathways which may help deliver
personalised medicine for PD is shown in Box 8. These range
from genomic medicine to subtype/syndrome and symptom
speciﬁc care.
Conclusion
PD is a motor and non-motor disorder from the onset of the
condition. Indeed, prodromal PD is largely non-motor. Key
advances include the development of validated tools for holistic
measurement ofNMS, grading of theNMSburden, and a focus on
multi-modal biomarkers to deﬁne non-motor PD subtypes. The
latter is likely to lead to better management of NMS in PD. Future
strategies should focus on developing robust animal models for
speciﬁc NMS to provide a better understanding of the patho-
physiology, which will enable development of personalised
treatment strategies. The under-recognition of the burden ofNMS
and its effects can be remedied by better education of clinicians
and caregivers. Only thenwill NMS cease to be the hidden painful
face of PD.
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